

1 **Title page**

2 **Type of manuscript:** Original article.

3 **Title:** Altered blood microbiome in patients with HCV-related decompensated cirrhosis.

4 **Running head:** Blood microbiome in cirrhosis

5 **Authors:** Oscar BROCHADO-KITH <sup>1,2</sup>; Marta RAVA <sup>3,2</sup>; Juan BERENGUER <sup>2,4,5</sup>; Juan GONZÁLEZ-  
6 GARCÍA <sup>6,7</sup>; David ROJO <sup>8</sup>; Cristina DíEZ <sup>2,4,5</sup>, Victor HONTAÑÓN <sup>6,7</sup>; Ana VIRSEDA-BERDICES <sup>1,2</sup>;  
7 Luis IBAÑEZ-SAMANIEGO <sup>9</sup>; Elba LLOP-HERRERA <sup>10</sup>; Antonio OLVEIRA <sup>11</sup>; Leire PEREZ-  
8 LATORRE<sup>2,4,5</sup>; Coral BARBAS <sup>8</sup>; Amanda FERNÁNDEZ-RODRÍGUEZ <sup>1,2</sup>; Salvador RESINO <sup>1,2,†,\*</sup>;  
9 María Angeles JIMÉNEZ-SOUSA <sup>1,2,†,\*</sup> and the ESCORIAL Study Group,

10 (†), The authors contributed equally to this work. (\*), Corresponding author.

11 **Authors' Affiliations:**

12 (1) Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto  
13 de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.

14 (2) Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC),  
15 Instituto de Salud Carlos III. Madrid. Spain.

16 (3) Unidad de la Cohorte de la Red de Investigación en Sida (CoRIS). Centro Nacional de  
17 Epidemiología, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

18 (4) Unidad de Enfermedades Infecciosas/VIH; Hospital General Universitario “Gregorio  
19 Marañón”, Madrid, Spain.

20 (5) Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.

21 (6) Servicio de Medicina Interna-Unidad de VIH. Hospital Universitario La Paz. Madrid, Spain.

22 (7) Instituto de Investigación Sanitaria La Paz (IdiPAZ). Madrid, Spain.

23 (8) Centre of Metabolomics and Bioanalysis (CEMBIO), Facultad de Farmacia, Universidad San  
24 Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28060 Boadilla del Monte, Spain

25 (9) Servicio de Aparato Digestivo, Hospital General Universitario “Gregorio Marañón”, Madrid,  
26 Spain.

27 (10) Departamento de Gastroenterología; Hospital Universitario Puerta de Hierro-Majadahonda;  
28 Majadahonda, Madrid; Spain.

29 (11) Servicio de Aparato Digestivo, Hospital Universitario La Paz, Madrid, Spain

30

31 **\*Corresponding author:** Maria Angeles Jiménez-Sousa; Centro Nacional de Microbiología,  
32 Instituto de Salud Carlos III (Campus Majadahonda); Carretera Majadahonda-Pozuelo, Km 2.2;  
33 28220 Majadahonda (Madrid); Phone: +34918223862. E-mail: [jimenezsosa@isciii.es](mailto:jimenezsosa@isciii.es).

34 **Co-Corresponding author:** Salvador Resino García; Centro Nacional de Microbiología,  
35 Instituto de Salud Carlos III (Campus Majadahonda); Carretera Majadahonda-Pozuelo, Km 2.2;  
36 28220 Majadahonda (Madrid); Phone: +34918223266. E-mail: [sresino@isciii.es](mailto:sresino@isciii.es).

37

## 38 **Declarations**

### 39 **Consent for publication**

40 Not applicable

### 41 **Availability of data and materials**

42 The datasets used and/or analyzed during the current study are available from the  
43 corresponding author upon reasonable request.

44 The raw sequences are publicly available at the European Nucleotide Archive repository  
45 (ENA; <https://www.ebi.ac.uk/>) under the accession number PRJEB65371.

## 46 **Competing interests**

47 The authors declare that they have no competing interests.

48 The funding sources played no role in the study's design, collection, analysis, interpretation of  
49 the data, or manuscript writing.

## 50 **Funding**

51 This study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant numbers  
52 CP17CIII/00007, PI18CIII/00028 and PI21CIII/00033 to MAJS, PI17/00657 and PI20/00474  
53 to JB, PI17/00903 and PI20/00507 to JGG, and PI17CIII/00003 and PI20CIII/00004 to SR)  
54 and Ministerio de Ciencia e Innovación (PID2021-126781OB-I00 funded by  
55 MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to AFR). The  
56 study was also funded by CIBER - Consorcio Centro de Investigación Biomédica en Red - (CB  
57 2021; CB21/13/00044), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and  
58 Unión Europea - NextGenerationEU. CB and DR acknowledge funding from the Ministerio de  
59 Ciencia, Innovación y Universidades (RTI2018-095166-B-I00). MAJS and MR are Miguel  
60 Servet researchers supported and funded by ISCIII (grant numbers: CP17CIII/00007 to MAJS  
61 and CP19CIII/00002 to MR).

## 62 **Acknowledgments**

63 This study would not have been possible without the collaboration of all the patients, medical  
64 and nursery staff, and data managers who participated in the project. We want to particularly  
65 acknowledge the support of the HIV BioBank, integrated into the Spanish AIDS Research  
66 Network and all collaborating Centres, for the generous contribution with clinical samples for  
67 the present work (see **Appendix**). The HIV BioBank is supported by Instituto de Salud Carlos  
68 III, Spanish Health Ministry (Grant nº RD06/0006/0035, RD12/0017/0037 and  
69 RD16/0025/0019) as part of the Plan Nacional R + D + I and cofinanced by ISCIII-  
70 Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER)". The

71 RIS Cohort (CoRIS) is funded by the Instituto de Salud Carlos III through the Red Temática de  
72 Investigación Cooperativa en SIDA (RIS C03/173, RD12/0017/0018 and RD16/0002/0006)  
73 as part of the Plan Nacional R+D+I and cofinanced by ISCIII-Subdirección General de  
74 Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER).

## 75 **Authorship contribution**

76 Funding body: MAJS, SR.

77 Study concept and design: MAJS.

78 Patients' selection and clinical data acquisition: CD, VH, JB, JGG, LIS, ELH, AO, LPL.

79 Sample preparation, and biomarker analysis: OBK, AVB, AFR, DR, CB.

80 Statistical analysis and interpretation of data: OBK, MR, MAJS.

81 Writing of the manuscript: OBK, MAJS.

82 Critical revision of the manuscript for relevant intellectual content: JB, JGG, DR, CB, AFR, MR,

83 SR.

84 Supervision and visualization: MAJS.

85 All authors read and approved the final manuscript.

## 86 **Ethical Approval statement**

87 The study received the approval of the Research Ethics Committee of the Instituto de Salud

88 Carlos III (CEI42\_2020, CEI41\_2014).

## 89 **Appendix**

### 90 **The ESCORIAL study group.**

91 **Hospital General Universitario Gregorio Marañón (Madrid, Spain):** Cristina Díez, Luis

92 Ibáñez, Leire Pérez-Latorre, Diego Rincón, Teresa Aldámiz-Echevarría, Vega Catalina, Pilar

93 Miralles, Teresa Aldámiz-Echevarría, Francisco Tejerina, María C Gómez-Rico, Esther Alonso,

94 José M Bellón, Rafael Bañares, and Juan Berenguer.

95 **Hospital Universitario La Paz/IdiPAZ** (Madrid, Spain): José Arribas, José I Bernardino,  
96 Carmen Busca, Javier García-Samaniego, Víctor Hontañón, Luz Martín-Carbonero, Rafael  
97 Micán, María L Montes-Ramírez, Victoria Moreno, Antonio Olveira, Ignacio Pérez-Valero,  
98 Eulalia Valencia, and Juan González-García.

99 **Hospital Universitario Puerta de Hierro** (Madrid, Spain): Elba Llop and José Luis Calleja.

100 **Hospital Universitario Ramón y Cajal** (Madrid, Spain): Javier Martínez and Agustín Albillos.

101 **Fundación SEIMC/GeSIDA** (Madrid, Spain): Marta de Miguel, María Yllescas, and Herminia  
102 Esteban.

103

## 104 **Abstract**

105 **Background:** Altered bacterial translocation is associated with transitioning from  
106 compensated to decompensated cirrhosis. Thus, we aimed to study differences in the blood  
107 microbiome of HCV-infected patients with and without hepatic decompensation.

108 **Methods:** We conducted a cross-sectional study in patients with advanced HCV-related cir-  
109 rhosis with or without human immunodeficiency virus (HIV) infection (n=88). MiSeq Illumina  
110 technology for bacterial 16S rRNA sequencing was used. Non-targeted metabolomics was per-  
111 formed by GC-MS and LC-MS ESI+ and ESI-.

112 **Results:** Patients with decompensated cirrhosis had lower levels of richness (Chao1), and  
113 alpha diversity (Shannon and Simpson indexes) at phylum level, than patients without  
114 decompensation. Likewise, we observed significant differences in beta diversity between  
115 groups at phylum, class and order levels, being lower in decompensated cirrhotic patients.  
116 Higher relative abundance of Proteobacteria (Fold Change (FC)=1.54, p=0.012),  
117 Alphaproteobacteria (FC=1.57, p=0.016) and Sphingomonadales (FC=1.61, p=0.050) were  
118 significantly associated with hepatic decompensation. The phylum Proteobacteria was posi-  
119 tively correlated with ethanolamine and oleic acid (p=0.005 and p=0.004, respectively) and

120 negatively with p-cresol ( $p=0.006$ ). In addition, the order Sphingomonadales was also nega-  
121 tively correlated with p-cresol ( $p=0.001$ ).

122 **Conclusions:** Blood microbial diversity was significantly decreased in patients with decompensated cirrhosis, who presented an enrichment of Proteobacteria, Alphaproteobacteria, and  
123 Sphingomonadales, compared to patients with compensated cirrhosis.  
124

125

126 **Key Words**

127 Chronic hepatitis C; HIV; cirrhosis; decompensation; microbiome; metabolome

## 128 **Background**

129 Hepatitis C virus (HCV) infection is considered one of the most notable causes of chronic liver  
130 disease worldwide. Without antiviral therapy, about 5-20% of HCV-infected patients will  
131 develop cirrhosis, increasing the risk of liver failure, hepatic decompensation, hepatocellular  
132 carcinoma (HCC), and death. Hepatic decompensation is considered the most important cause  
133 of hospitalization among cirrhotic patients and a major risk factor for death [1].

134 Decompensated cirrhosis has an annual mortality rate of 57%, and 30% mortality is  
135 associated with acute decompensating events [2]. Traditionally, non-invasive indexes have  
136 been used to triage patients with advanced liver diseases. Among them, the Child-Turcotte-  
137 Pugh (CTP) score is an essential indicator of severity, determining the cirrhosis status and  
138 predicting morbidity and mortality.

139 The gut microbiota and bacterial translocation may influence liver disease progression in  
140 patients with viral hepatitis [3]. Likewise, gut microbiota dysbiosis and sustained bacterial  
141 translocation have been observed among people living with human immunodeficiency virus  
142 (HIV) despite the use of antiretroviral therapy (ART) [4]. In this setting, bacterial overgrowth  
143 increases intestinal permeability, and defects in gut-associated lymphatic tissue in patients  
144 with advanced liver disease promote impaired bacterial translocation, which leads to severe  
145 liver damage by several mechanisms related to persistent immune activation and  
146 inflammation [5]. Thus, altered bacterial translocation is associated with transitioning from  
147 compensated to decompensated cirrhosis [6].

148 In this context, the presence in the blood of certain bacteria or bacterial products, and the  
149 finding of specific microbiome patterns, could constitute an innovative approach for a better  
150 understanding of the pathogenesis of advanced HCV-related cirrhosis. So far, scarce studies  
151 have investigated the blood microbiome in decompensated cirrhotic patients. Trakova *et al.*  
152 [7] found a markedly higher number of bacterial species than control individuals. Alvarez-

153 Silva *et al.* [8] described a relationship between the microbiota composition and systemic  
154 inflammation in the blood. However, to our knowledge, none of the previous studies focused  
155 on studying the role of the blood microbiome among HCV-infected patients with hepatic  
156 decompensation.

157 **Objective**

158 We aimed to study differences in the blood microbiome of HCV-infected patients with and  
159 without hepatic decompensation.

160

161



## 162 **Methods**

### 163 **Study subjects**

164 We performed a cross-sectional study in patients with advanced HCV-related cirrhosis with or  
165 without HIV, recruited at four tertiary referral hospitals in Madrid (Spain) between January  
166 2015 and June 2016. The study received the approval of the Research Ethics Committee of the  
167 Instituto de Salud Carlos III (CEI42\_2020, CEI41\_2014) and was carried out following the  
168 Declaration of Helsinki. All participants of the study gave their written informed consent.

169 The selection criteria were: 1) demonstrable active HCV infection by polymerase chain  
170 reaction (PCR); 2) advanced cirrhosis defined by any of the following criteria: i) prior history  
171 of ascites, bleeding esophageal varices, or hepatic encephalopathy; ii) liver stiffness  $\geq 25$  kPa;  
172 iii) CTP  $\geq 7$ ); and/or iii) clinically significant portal hypertension defined as an hepatic venous  
173 pressure gradient (HVPG)  $\geq 10$  mmHg; 3) available CTP score; 4) available blood sample for  
174 microbiome analysis. HIV/HCV-coinfected patients had a stable ART for over six months and  
175 undetectable plasma HIV viral load ( $< 50$  copies/mL).

### 176 **Samples**

177 Approximately 30-40 mL of whole blood was collected from each patient in EDTA tubes,  
178 which were sent to the HIV Biobank (<http://hivhgmbiobank.com/?lang=en>), where they were  
179 processed and stored at  $-80$  °C until use. The epidemiological and clinical variables were  
180 collected using an online form within each center, which fulfilled data confidentiality  
181 requirements.

### 182 **Outcome variable**

183 The outcome was hepatic decompensation, defined as a CTP score  $\geq 7$ . CTP score was  
184 calculated from five routine laboratory parameters and clinical measures of liver disease

185 (serum albumin, total bilirubin, international normalized ratio (INR), ascites, and hepatic  
186 encephalopathy) (<https://www.hepatitisc.uw.edu/page/clinical-calculators/ctp>).

## 187 **Blood microbiome**

188 Whole blood samples were used for DNA extraction and subsequent 16S targeted  
189 metagenomic sequencing in a strictly controlled environment. It was carried out at Vaiomer  
190 (Toulouse, France), a biotech company expert in tissue and blood microbiota, which uses a  
191 rigorous contamination-aware approach, described and discussed elsewhere [9-11].

192 DNA was extracted from 50 µl of each whole blood sample using an optimized tissue-specific  
193 technique, as previously described [9, 11]. The quality and quantity of extracted nucleic acids  
194 were controlled by gel electrophoresis and NanoDrop 2000 UV spectrophotometer (Thermo  
195 Scientific).

196 Library preparation was performed by two-step PCR amplification using 16S universal  
197 primers targeting the V3–V4 region of the bacterial 16S ribosomal DNA (rDNA), as described  
198 previously [10]. The resulting amplicon of approximately 467 base pairs was sequenced using  
199 2 x 300 paired-end MiSeq kit V3. For each sample, a sequencing library was generated by the  
200 addition of sequencing adapters. The detection of the sequencing fragments was performed  
201 using MiSeq Illumina technology.

202 The targeted metagenomic sequences from microbiota were analyzed using the  
203 bioinformatics pipeline established by Vaiomer based on the Find, Rapidly, OTUs with Galaxy  
204 Solution guidelines. Briefly, after demultiplexing the barcoded Illumina paired reads, single-  
205 read sequences were cleaned and paired for each sample independently into longer  
206 fragments. Operational taxonomic units (OTUs) were produced via single-linkage clustering  
207 using the Swarm algorithm and its adaptive sequence agglomeration [12]. The taxonomic  
208 assignment was performed against the Silva v132 database to determine taxonomic profiles.  
209 The following specific filters were applied for this analysis to obtain the best results: (1) the

210 last ten bases of reads R1 were removed; (2) the last 40 bases of reads R2 were removed; (3)  
211 amplicons with a length of <350 or >500 nucleotides were removed; (4) OTUs with  
212 abundance <0.005% of the whole dataset abundance were removed. To ensure the low impact  
213 of the potential DNA contamination from the environment and especially from reagents,  
214 negative controls were added and carried over throughout the 16S rRNA gene sequencing  
215 pipeline. Negative controls were performed for the DNA extraction and amplification steps  
216 with molecular grade water as starting material. Positive controls with a mock community  
217 were also added during the sequencing library preparation.

### 218 **Non-targeted metabolomics**

219 Firstly, methanol was mixed with plasma samples (3:1, v/v) for viruses' inactivation. Then, samples  
220 were vortexed (15 sec), maintained cold for 5 min, centrifuged (16000 g, 20 min, 4°C), and frozen  
221 (-80°C) before being sent to the Center for Metabolomics and Bioanalysis (CEU-San Pablo  
222 University, Pozuelo de Alarcón, Spain). On the day of analysis, the samples were correctly  
223 processed and subsequently analyzed by gas chromatography-mass spectrometry (GC-MS) and  
224 liquid chromatography-mass spectrometry (LC-MS) with positive and negative electrospray  
225 ionization (ESI). Quality controls were prepared by pooling and mixing equal volumes of each  
226 corresponding sample independently for each analytical platform (full description in  
227 **Supplementary\_file\_1**).

228 For the deconvolution and identification process in GC-MS, MassHunter Quantitative Unknown  
229 analysis (B.07.00, Agilent) was used. Alignment was carried out with MassProfiler Professional  
230 software (version 13.0, Agilent), and Masshunter Quantitative Analysis (version B.07.00, Agilent)  
231 was used for peak integration. In LC-MS, the Molecular Feature Extraction and the Recursive  
232 Feature Extraction algorithms in the MassHunter Profinder software (B.08.00, Agilent) were used  
233 for deconvolution, peak integration, and alignment of the raw data (more details are available in  
234 **Supplementary\_file\_1**).

## 235 **Statistical analysis**

236 For the descriptive study, quantitative variables were expressed as median (interquartile  
237 range) and categorical variables as absolute count (percentage). When comparing data  
238 between groups, we used Fisher's exact test for categorical and unpaired Wilcoxon rank-sum  
239 test for continuous variables.

240 Regarding the metagenomics data, richness (Chao1 estimator), alpha diversity (Shannon and  
241 Simpson index), and beta diversity (Weighted Unifrac distance, Bray-Curtis dissimilarity,  
242 Jaccard index) of bacterial communities were calculated (Vegan package V. 2.5-7). Richness  
243 and alpha diversity indexes were analyzed in association with hepatic decompensation, here  
244 considered as an independent variable, by the Wilcoxon rank-sum test and multivariable  
245 generalized linear model (GLM) with a gamma distribution, unadjusted and adjusted by HIV  
246 coinfection (included as covariate in the model). Besides, we compared beta diversity  
247 between groups by using principal coordinates analysis (PCoA) plots and permutational  
248 MANOVA.

249 For analyzing differences in the relative abundance of OTUs between groups, we first  
250 normalized the initial data at each taxonomic level and filtered those taxa that did not reach  
251 the minimum abundant level for the analysis (at least appeared in 10% of the samples).

252 Subsequently, we carried out univariable and multivariable analyses. Univariable analysis was  
253 performed using the Wilcoxon rank-sum test, a non-parametric test that compares the  
254 relative abundances of bacterial taxa between groups. The false discovery rate (FDR) was  
255 applied to account for multiple comparison, and adjusted p-values (q-values) were calculated  
256 according to the Benjamini-Hochberg method. Those taxa with  $p < 0.05$  and  $q < 0.150$  were  
257 included in the multivariable models. Multivariable analyses were carried out using the  
258 `aldex.glm` function from the ALDEx2 package (v. 1.22.0), and HIV coinfection was included as  
259 a covariate.

260 Finally, we selected the bacterial taxa significantly different in the relative abundance  
261 between groups, and we estimated the correlation with plasma metabolomic data from GC-  
262 MS, LC-MS ESI+, and LC-MS ESI- using the Spearman rank order correlation test. The  
263 correlations were considered relevant when  $r > 0.3$  or  $r < -0.3$  and  $q < 0.150$ .

264 All the analyses were carried out by using R statistical package (R Foundation for Statistical  
265 Computing, Vienna, Austria, v. 4.0.5).

266

267

## 268 **Results**

### 269 **Characteristics of the study population**

270 A total of 88 patients were included, 61 with HIV, whose characteristics stratified by their  
271 stage of cirrhosis (compensated vs. decompensated) are shown in **Table 1**. Among patients  
272 with compensated cirrhosis (n=75), the mean age was 53.1 years, and 65% were male.  
273 Patients with decompensated cirrhosis (n=13) had a mean age of 52.1 years, and 92.3% were  
274 male. Of note, decompensated patients were less frequently coinfecting with HIV ( $p = 0.019$ ).

### 275 **Microbiome analysis**

#### 276 A) Richness and alpha diversity

277 Decompensated patients showed lower richness at phylum (Chao1,  $p=0.032$ ) and class levels  
278 (Chao1,  $p=0.020$ ) than compensated patients (**Figure1**). Regarding alpha diversity,  
279 decompensated patients showed lower levels of Shannon ( $p=0.005$ ) and Simpson indexes  
280 ( $p=0.003$ ) at the phylum level than compensated patients (**Figure1**).

281 After adjustment for HIV coinfection in a gamma GLM model, we found that decompensated  
282 patients had lower levels of Chao1 estimator at the phylum (adjusted arithmetic mean ratio  
283 (aAMR)=0.85,  $p=0.021$ ) and class level (aAMR=0.85,  $p=0.019$ ) than compensated patients.

284 Regarding alpha diversity, decompensated patients showed lower levels of Shannon  
285 (aAMR=0.80,  $p=0.005$ ) and Simpson indexes (aAMR=0.83,  $p=0.006$ ) at the phylum level than  
286 compensated patients (**Supplementary\_file\_2**).

#### 287 B) Beta diversity

288 Beta-diversity was significantly different between compensated and decompensated patients,  
289 finding lower beta-diversity at the phylum level (Jaccard:  $p=0.049$ ), class level (Weighted  
290 Unifrac:  $p=0.040$ , Bray-Curtis:  $p=0.017$ , Jaccard:  $p=0.028$ ), and order level (Weighted Unifrac:  
291  $p=0.016$ , Bray-Curtis:  $p=0.047$ ) in decompensated patients, as determined using PCoA plots

292 and permutational MANOVA. In addition, these significant differences were maintained when  
293 models were adjusted by HIV coinfection at the phylum level (Jaccard: adjusted  $p=0.046$ ),  
294 class level (Weighted Unifrac: adjusted  $p=0.033$ , Bray-Curtis: adjusted  $p=0.018$ ), and order  
295 level (Weighted Unifrac: adjusted  $p=0.019$ , Bray-Curtis: adjusted  $p=0.048$ ) (**Figure2**,  
296 **Supplementary\_file\_3**).

### 297 C) Relative abundances

298 We assessed the differences in the relative abundance at all taxonomic levels between  
299 decompensated and compensated patients. Decompensated patients had a higher relative  
300 abundance of the phylum Proteobacteria ( $p=0.004$ ), the class Alphaproteobacteria ( $p\leq 0.001$ ),  
301 the orders Sphingomonadales ( $p\leq 0.001$ ) and Oceanospirillales ( $p=0.047$ ), families  
302 *Sphingomonadaceae* ( $p=0.002$ ), *Paenibacillaceae* ( $p=0.038$ ) and *Microbacteriaceae* ( $p=0.043$ ),  
303 and genus *Bradyrhizobium* ( $p=0.001$ ), *Sphingomonas* ( $p=0.009$ ) and *Rhodococcus* ( $p=0.027$ )  
304 than compensated patients. However, only the phylum Proteobacteria ( $q=0.037$ ), the class  
305 Alphaproteobacteria ( $q=0.006$ ), the order Sphingomonadales ( $q=0.050$ ), family  
306 *Sphingomonadaceae* ( $q=0.090$ ) and genus *Bradyrhizobium* ( $q=0.087$ ) were considered  
307 relevant after adjusting for multiple comparisons (FDR,  $q<0.150$ ) (**Table 2**). When HIV  
308 coinfection was taken into account for adjusting the models by ALDEx2, a higher relative  
309 abundance of Proteobacteria ( $p=0.012$ ), Alphaproteobacteria ( $p=0.016$ ), and  
310 Sphingomonadales ( $p=0.050$ ) remained significantly associated with hepatic decompensation.  
311 Boxplots for the relative abundances of these significant bacterial taxa are shown in  
312 **Supplementary\_file\_4**.

### 313 **Correlation analysis with metabolomic data**

314 The correlation between bacterial taxa related to hepatic decompensation and metabolomic  
315 data was studied. Regarding GC-MS data, we observed a significant positive correlation of the  
316 phylum *Proteobacteria* with ethanolamine and oleic acid ( $r=0.330$ ,  $p=0.005$ ,  $q=0.115$  and

317  $r=0.302$ ,  $p=0.004$ ,  $q=0.115$ , respectively) and a significant negative correlation with p-cresol  
318 ( $r=-0.308$ ,  $p=0.006$ ,  $q=0.115$ ). In addition, the order *Sphingomonadales* was negatively  
319 correlated with p-cresol ( $r=-0.354$ ,  $p=0.001$ ,  $q=0.112$ ) (**Figure3, Supplemental File 5**).  
320 Regarding LC-MS data, we found a significant negative correlation between the order  
321 *Sphingomonadales* and p-cresol ( $r=-0.367$ ,  $p=0.001$ ,  $q=0.122$ ) (**Figure3,**  
322 **Supplementary\_file\_5**).

323

324



## 325 **Discussion**

326 We compared the blood microbiome between HCV-infected patients with decompensated and  
327 compensated cirrhosis, finding lower alpha and beta diversity richness in the first ones. We  
328 also found that the relative abundance of Proteobacteria, Alphaproteobacteria, and  
329 Sphingomonadales was higher in decompensated patients. The dysbiosis of the blood  
330 microbiome was accompanied by changes in metabolites related to liver reparation processes  
331 and microbiota fermentation.

332 Although several studies have previously investigated the blood microbiome in cirrhosis, few  
333 articles have described its role among HCV-infected cirrhotic patients. Recently, Gedgaudas *et*  
334 *al.* found that circulating microbiome profiles in patients with cirrhosis were distinct from  
335 those of healthy individuals, with enrichment of the genera *Bacteroides*, *Escherichia/Shigella*,  
336 and *Prevotella* in patients with portal hypertension [13]. However, this study included  
337 patients with cirrhosis of different etiologies and analyzed plasma instead of whole blood  
338 [13]. Traykova *et al.* studied the blood microbiome in nine patients with decompensated  
339 cirrhosis compared to controls, finding that the bacterial microbiome is related to changes in  
340 systemic vascular resistance and cardiac outcomes [7]. However, they only screened for 53  
341 specific bacteria from the gut in the blood [7]. Moreover, our group previously found an  
342 association between specific bacterial taxa before HCV therapy, such as *Corynebacteriales* and  
343 *Massilia*, and a decrease in HVPG in patients with HCV-related cirrhosis after direct-acting  
344 antiviral therapy for HCV [14]. Thus, to our knowledge, this is the first study in which the  
345 circulating microbiome from patients with compensated and decompensated HCV-related  
346 cirrhosis has been compared, providing new insight into the potential mechanisms underlying  
347 this liver injury status.

348 In our study, patients with decompensated cirrhosis had lower richness and alpha diversity  
349 for different taxonomic ranks than patients with compensated cirrhosis. These findings are

350 consistent with previous data supporting that less diverse gut microbiome ecosystems are  
351 associated with poorer body health status, probably because reduced species diversity leads  
352 to lower efficient systems [15]. Regarding viral hepatitis and gut microbiome, a less diverse  
353 microbiome has been previously described in the gut of cirrhotic patients with hepatitis B and  
354 C compared to healthy controls, finding significant differences in the microbiota community  
355 between groups [16, 17]. Moreover, an improvement in gut microbiota diversity was also  
356 observed in responders achieving a sustained virological response after anti-HCV therapy;  
357 however, patients with more advanced fibrosis stages showed lower improvement [16]. In  
358 this line, while changes in the diversity of gut microbiome are getting deeply studied, there is  
359 scarce data about diversity changes in blood microbiome among patients with viral hepatitis.  
360 In a recent study, a trend towards lower bacterial diversity with worse disease stage was  
361 described in the context of hepatitis B and D infection [18], which is consistent with what we  
362 observed in patients with HCV-related cirrhosis.

363 Regarding the beta diversity, which represents the number of overlapping taxa between  
364 samples, microbiome signature differences between compensated and decompensated  
365 patients were consistently found for phylum, class, and order taxonomic ranks, and  
366 corroborated by several indexes, with PCoA helping us to visualize these differences. In  
367 previous studies, separate clustering between patients with liver disease induced by viral  
368 hepatitis C and healthy controls was described in the gut [19]. However, similar to alpha  
369 diversity, information in the literature is sparse, and to our knowledge, this is the first report  
370 studying differences in beta diversity between different cirrhosis stages in blood.

371 We also detected an association between a higher relative abundance of Proteobacteria,  
372 Alphaproteobacteria, and Sphingomonadales and hepatic decompensation. Proteobacteria has  
373 been described as a potential microbial signature of dysbiosis and disease risk [20]. A study  
374 by Sun et al. documented that the phylum Proteobacteria, among others, was increased in

375 patients with chronic B cirrhosis [17]. Alphaproteobacteria, a class rank belonging to the  
376 phylum Proteobacteria, is classified as one of the most diverse bacterial subdivisions  
377 influencing host-cell proliferation [21]. The order Sphingomonadales, which is part of the  
378 class Alphaproteobacteria, appears to be relatively more abundant in patients with hepatic  
379 decompensation. Bacteria from the Sphingomonadales order are known to have  
380 lipoxygenases that may have a vital role in bacteria-host signaling [22]. All these findings in  
381 the literature support the significant association with hepatic decompensation found in our  
382 study. In regards to the *Sphingomonadaceae* family, we found a trend of association between  
383 the relative abundance of this family and hepatic decompensation.

384 Dysbiosis in environments such as the gut or oral cavity often goes hand in hand with  
385 metabolic changes and disease progression [23]. Regarding the blood, we observed that  
386 metabolic changes also accompanied microbiome dysbiosis. The phylum Proteobacteria was  
387 directly associated with two metabolites in this study, ethanolamine and oleic acid. Firstly,  
388 ethanolamine, a source of nitrogen and carbon by diverse bacteria, has been associated with  
389 liver reparation processes in the damaged liver [24]. Secondly, oleic acid is a  
390 monounsaturated fatty acid with numerous beneficial properties in various animal and  
391 vegetable sources. In liver injuries, oleic acid recruitment from other tissues has been  
392 described as one of the rescue systems [25]. Some studies have observed its role in inhibiting  
393 chemotaxis and attenuating inflammation [26]. Additionally, we found an inverse correlation  
394 of the relative abundance of the phylum Proteobacteria, the order Sphingomonadales, and the  
395 family *Sphingomonadaceae* with the p-cresol, being found by different analytical platforms  
396 (GC-MS and LC-MS). P-cresol is originated by fermentation from the microbiota. Based on  
397 previous microbiological studies, since bacteria of the phylum Proteobacteria are Gram-  
398 negative, their cell envelope is more sensitive to p-cresol, so it is consistent that in the absence  
399 of this metabolite, these taxa could grow freely in the blood and promote dysbiosis [27].  
400 Besides, Ikematsu *et al.*, in forensic autopsy cases, suggested that low levels of p-cresol in

401 blood could be explained by an accumulation of p-cresol in the liver in cases of liver diseases  
402 [28].

403 Additionally, it is crucial to note that this study was performed using a strict contamination-  
404 aware approach. Firstly, any potential contamination by needle with the skin microbiome was  
405 prevented by the high volume of blood withdrawn. Secondly, positive and negative controls  
406 were used throughout the sequencing pipeline in order to control any impact of the environ-  
407 ment on the results. Thirdly, to avoid possible confusion with HIV coinfection, multivariate  
408 models including HIV status as a covariate were carried out, controlling the possible con-  
409 founding effects of HIV-coinfection. Finally, adjustment for multiple comparison was per-  
410 formed, avoiding false significant associations. All of these approaches provide robustness to  
411 our data.

412 The following considerations should be taken into account for a correct interpretation of the  
413 results. Firstly, this study had a cross-sectional design; therefore, it does not allow us to  
414 determine the causal relationship of the findings. Secondly, the sample size was limited, which  
415 could restrict the statistical power to detect other significant differences in bacterial taxa  
416 between groups. Moreover, we could not carry out the statistical analysis separately for HCV-  
417 monoinfected and HIV/HCV-coinfected patients due to the limited sample size. Nevertheless,  
418 possible confusion with HIV coinfection was ruled out by including HIV status as a covariate in  
419 multivariate models.

## 420 **Conclusions**

421 In conclusion, blood microbial diversity was significantly decreased in patients with  
422 decompensated HCV-related cirrhosis, who presented an enrichment of Proteobacteria,  
423 Alphaproteobacteria, and Sphingomonadales, compared to patients with compensated  
424 cirrhosis. The dysbiosis of the blood microbiome was accompanied by metabolomic changes.

425 Further studies are needed to decipher the impact that blood microbial dysbiosis could have  
426 on these patients and strategies to correct it.

427

## 428 **Abbreviations**

429 aAMR: Adjusted arithmetic mean ratio

430 AMR: Arithmetic mean ratio

431 ART: Antiretroviral therapy

432 CTP: Child-Turcotte-Pugh

433 ESI: Electrospray ionization

434 FC: Fold Change

435 FDR: False discovery ratio

436 GC-MS: Gas chromatography-mass spectrometry

437 GLM: Generalized linear model

438 HCC: Hepatocellular carcinoma

439 HCV: Hepatitis C virus

440 HIV: Human immunodeficiency virus

441 HVPG: Hepatic venous pressure gradient

442 INR: International normalized ratio

443 LC-MS: Liquid chromatography-mass spectrometry

444 MANOVA: Multivariate analysis of variance

445 OTU: Operative taxonomic Unit

446 PCoA: Principal coordinates analysis

447 PCR: Polymerase chain reaction

448

449

## 450 **References**

- 451 [1] D'Amico G, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis. *J*  
452 *Hepatol* 2022; 76:202-207.
- 453 [2] Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet* 2014; 383:1749-1761.
- 454 [3] Sandler NG, Koh C, Roque A *et al*. Host response to translocated microbial products  
455 predicts outcomes of patients with HBV or HCV infection. *Gastroenterology* 2011; 141:1220-  
456 1230, 1230 e1221-1223.
- 457 [4] Ishizaka A, Koga M, Mizutani T *et al*. Unique Gut Microbiome in HIV Patients on  
458 Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation. *Microbiol*  
459 *Spectr* 2021; 9:e0070821.
- 460 [5] Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to  
461 Hepatic Disorders. *Gastroenterology* 2020; 159:849-863.
- 462 [6] Jalan R, Gines P, Olson JC *et al*. Acute-on chronic liver failure. *J Hepatol* 2012; 57:1336-  
463 1348.
- 464 [7] Traykova D, Schneider B, Chojkier M, Buck M. Blood Microbiome Quantity and the  
465 Hyperdynamic Circulation in Decompensated Cirrhotic Patients. *PLoS One* 2017;  
466 12:e0169310.
- 467 [8] Alvarez-Silva C, Schierwagen R, Pohlmann A *et al*. Compartmentalization of Immune  
468 Response and Microbial Translocation in Decompensated Cirrhosis. *Front Immunol* 2019;  
469 10:69.
- 470 [9] Anhe FF, Jensen BAH, Varin TV *et al*. Type 2 diabetes influences bacterial tissue  
471 compartmentalisation in human obesity. *Nat Metab* 2020; 2:233-242.
- 472 [10] Lluch J, Servant F, Paisse S *et al*. The Characterization of Novel Tissue Microbiota Using an  
473 Optimized 16S Metagenomic Sequencing Pipeline. *PLoS One* 2015; 10:e0142334.
- 474 [11] Schierwagen R, Alvarez-Silva C, Servant F *et al*. Trust is good, control is better: technical  
475 considerations in blood microbiome analysis. *Gut* 2020; 69:1362-1363.
- 476 [12] Escudie F, Auer L, Bernard M *et al*. FROGS: Find, Rapidly, OTUs with Galaxy Solution.  
477 *Bioinformatics* 2018; 34:1287-1294.
- 478 [13] Gedgaudas R, Bajaj JS, Skieceviciene J *et al*. Circulating microbiome in patients with portal  
479 hypertension. *Gut Microbes* 2022; 14:2029674.
- 480 [14] Virseda-Berdices A, Brochado-Kith O, Diez C *et al*. Blood microbiome is associated with  
481 changes in portal hypertension after successful direct-acting antiviral therapy in patients with  
482 HCV-related cirrhosis. *J Antimicrob Chemother* 2022; 77:719-726.
- 483 [15] Larsen OFA, Claassen E. The mechanistic link between health and gut microbiota  
484 diversity. *Sci Rep* 2018; 8:2183.

- 485 [16] Chuaypen N, Jinato T, Avihingsanon A *et al.* Improvement of Gut Diversity and  
486 Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or  
487 Without Human Immunodeficiency Virus Coinfection. *J Infect Dis* 2021; 224:1410-1421.
- 488 [17] Sun X, Chi X, Zhao Y *et al.* Characteristics and Clinical Significance of Intestinal Microbiota  
489 in Patients with Chronic Hepatitis B Cirrhosis and Type 2 Diabetes Mellitus. *J Diabetes Res*  
490 2022; 2022:1826181.
- 491 [18] Townsend EC, Zhang GY, Ali R *et al.* Microbial Translocation in the Context of Hepatitis B  
492 Infection and Hepatitis D Infection. *Open Forum Infect Dis* 2021; 8:ofaa496.
- 493 [19] Ullah N, Kakakhel MA, Khan I *et al.* Structural and compositional segregation of the gut  
494 microbiota in HCV and liver cirrhotic patients: A clinical pilot study. *Microb Pathog* 2022;  
495 171:105739.
- 496 [20] Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut  
497 microbiota. *Trends Biotechnol* 2015; 33:496-503.
- 498 [21] Ettema TJ, Andersson SG. The alpha-proteobacteria: the Darwin finches of the bacterial  
499 world. *Biol Lett* 2009; 5:429-432.
- 500 [22] Kurakin GF, Samoukina AM, Potapova NA. Bacterial and Protozoan Lipoxygenases Could  
501 be Involved in Cell-to-Cell Signaling and Immune Response Suppression. *Biochemistry (Mosc)*  
502 2020; 85:1048-1071.
- 503 [23] Wilmanski T, Rappaport N, Earls JC *et al.* Blood metabolome predicts gut microbiome  
504 alpha-diversity in humans. *Nat Biotechnol* 2019; 37:1217-1228.
- 505 [24] Murakami T, Nagamura Y, Hirano K. Ethanolamine stimulates repair processes in acute  
506 CCl4 damage of mouse liver. *Toxicol Lett* 1998; 94:137-144.
- 507 [25] Piccinin E, Cariello M, De Santis S *et al.* Role of Oleic Acid in the Gut-Liver Axis: From Diet  
508 to the Regulation of Its Synthesis via Stearoyl-CoA Desaturase 1 (SCD1). *Nutrients* 2019; 11.
- 509 [26] Malawista SE, de Boisfleury Chevance A, van Damme J, Serhan CN. Tonic inhibition of  
510 chemotaxis in human plasma. *Proc Natl Acad Sci U S A* 2008; 105:17949-17954.
- 511 [27] Passmore IJ, Letertre MPM, Preston MD *et al.* Para-cresol production by *Clostridium*  
512 *difficile* affects microbial diversity and membrane integrity of Gram-negative bacteria. *PLoS*  
513 *Pathog* 2018; 14:e1007191.
- 514 [28] Ikematsu N, Kashiwagi M, Hara K *et al.* Diagnostic meaning of blood p-cresol  
515 concentration in forensic autopsy cases. *Leg Med (Tokyo)* 2018; 34:27-35.  
516
- 517

519 **Table 1.** Clinical and epidemiological characteristics of patients with HCV-related advanced  
520 cirrhosis.

521

<b>Characteristic</b>	<b>Compensated</b>	<b>Decompensated</b>	<b>P-value</b>
<b>No.</b>	75	13	
<b>Age (years)</b>	53.1 [50.5-56.1]	52.1 [46.6-56.4]	0.301
<b>Gender (male %)</b>	49/75[65.33%]	12/13[92.3%]	0.058
<b>BMI (kg/m<sup>2</sup>)</b>	24.2[22.1-27.7]	26.7[23.9-27.9]	0.198
<b>Smoker</b>			0.389
Never	16/75[21.3%]	1/13 [7.7%]	
> 6 months	17/75 [22.7%]	5/13 [38.5%]	
Currently	42/75 [56%]	7/13 [53.9%]	
<b>Alcohol intake</b>			0.376
Never	39/75 [52.0%]	5/13 [38.5%]	
> 6 months	31/75 [41.3%]	6/13 [46.2%]	
Currently	5/75 [6.7%]	2/13 [15.4%]	
<b>IVDU</b>	44/75[58.7%]	8/13[61.5%]	0.999
<b>HCV genotype 1</b>	51/75[68.0%]	7/11[57.1%]	0.743
<b>HCV viral load (log<sub>10</sub>)</b>	6.2[5.7-6.6]	5.79 [5.2-6.2]	0.053
<b>Previous anti-HCV treatment</b>	36/75[48.0%]	7/13 [53.9%]	0.770
<b>Statins</b>	9/75[12.0%]	0/13 [0%]	0.345
<b>Coinfection (HIV)</b>	56/75[74.7%]	5/13 [38.5%]	<b>0.019</b>
<b>CD4<sup>+</sup>/mm<sup>3</sup></b>	446.5[239.3-719.5]	378.0[164.0-685.0]	0.502
<b>Nadir CD4 cells</b>	119.0[63.0-232.5]	207.0[144.0-300.0]	0.131
<b>AIDS</b>	37/56[66.1%]	3/5[60.0%]	0.999

522

523 **Statistics:** Continuous variables were expressed as median [interquartil range], and p-values  
524 were calculated by the Wilcoxon rank-sum test. Categorical variables were expressed as  
525 absolute count [percentage], and p-values were calculated by the Fisher exact test.

526 **Abbreviations:** CTP, Child-Turcotte-Pugh; BMI, Body mass index; IVDU, Intravenous drugs  
527 user; HCV, Hepatitis C virus; HIV, Human immunodeficiency virus; AIDS, Acquired immune  
528 deficiency syndrome.

529



530 **Table 2.** Association between relative abundance of blood bacterial taxa and HCV-related decompensated cirrhosis.

531

<b>Bacterial taxa</b>		<b>Univariate</b>		<b>Multivariate</b>	
<b>Taxonomic rank</b>	<b>Taxa</b>	<b>p-value</b>	<b>FDR</b>	<b>Estimate</b>	<b>p-value</b>
Phylum	Proteobacteria	<b>0.004</b>	<b>0.037</b>	1.490	<b>0.012</b>
Class	Alphaproteobacteria	<b>≤0.001</b>	<b>0.006</b>	2.340	<b>0.016</b>
Order	Sphingomonadales	<b>≤0.001</b>	<b>0.036</b>	4.003	<b>0.050</b>
	Oceanospirillales	<b>0.047</b>	0.810	1.307	0.417
Family	Sphingomonadaceae	<b>0.002</b>	<b>0.090</b>	3.693	0.075
	Paenibacillaceae	<b>0.038</b>	0.759	1.030	0.515
	Microbacteriaceae	<b>0.043</b>	0.759	2.410	0.214
Genus	Bradyrhizobium	<b>0.001</b>	<b>0.087</b>	1.612	0.376
	Sphingomonas	<b>0.009</b>	0.377	2.873	0.174
	Rhodococcus	<b>0.027</b>	0.623	2.518	0.145


532

533 **Statistics:** P-values were calculated by univariate (Wilcoxon rank-sum test) and multivariate models (ALDEx2 package) adjusting by HIV  
534 coinfection as a covariate. FDR was calculated by Benjamini and Hochberg correction.

535 **Abbreviations:** FDR, false discovery ratio; FC, fold change; HIV, Human immunodeficiency virus.

536 **Figures**


537 **Figure1.** Representation of richness and alpha-diversity indexes for patients with  
538 compensated and decompensated cirrhosis. A) Chao1 estimator: it is calculated by taking the  
539 number of different species and also considering as relevant the number of species that were  
540 detected once (singletons) or twice (doubletons). B) Shannon index: it is based on the formula  
541 to describe entropy and how difficult it is to predict the next microbe detection when the  
542 diversity is high. C) Simpson index: it measures the probability that two individuals randomly  
543 selected from a sample will belong to the same taxa. Differences between groups were  
544 calculated by using Wilcoxon signed-rank test and expressed as p-values.



545

546


547 **Figure2.** Principal coordinates analysis (PCoA) representing the beta diversity for patients  
548 with compensated and decompensated cirrhosis. Statistics: P-values were calculated from a  
549 permutational univariate and multivariate analysis of variance adjusted for HIV-coinfection.



550

551

552 **Figure3.** Correlation between blood significant bacterial taxa and plasma metabolites.  
 553 Statistics: Direct correlations are shown in blue while inverse correlations are shown in red.  
 554 Asterisks indicate those correlations with a value of p-value<0.05 and q-value≤ 0.15 (q-values  
 555 (FDR) were calculated from Spearman correlation p-values.



556